

Title (en)
MODULATORS OF PROTEASE ACTIVATED RECEPTORS

Title (de)
MODULATOREN VON PROTEASEAKTIVIERTEN REZEPTOREN

Title (fr)
MODULATEURS DES RÉCEPTEURS ACTIVÉS PAR LES PROTÉASES

Publication
EP 2598517 A4 20141126 (EN)

Application
EP 11811656 A 20110728

Priority

- AU 2010903378 A 20100728
- AU 2011000959 W 20110728

Abstract (en)
[origin: WO2012012843A1] The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of -or susceptible to- a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.

IPC 8 full level
A61K 38/05 (2006.01); **A61K 38/06** (2006.01); **A61P 1/00** (2006.01); **A61P 3/00** (2006.01); **A61P 7/00** (2006.01); **A61P 9/00** (2006.01); **A61P 11/00** (2006.01); **A61P 13/00** (2006.01); **A61P 17/00** (2006.01); **A61P 19/00** (2006.01); **A61P 21/00** (2006.01); **A61P 25/00** (2006.01); **A61P 29/00** (2006.01); **A61P 37/00** (2006.01); **C07K 5/062** (2006.01); **C07K 5/065** (2006.01); **C07K 5/078** (2006.01); **C07K 5/083** (2006.01); **C07K 5/097** (2006.01)

CPC (source: EP US)
A61P 1/00 (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 1/18** (2017.12 - EP); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 7/12** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/00** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 19/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/08** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 5/00** (2013.01 - US); **C07K 5/06034** (2013.01 - EP US); **C07K 5/06078** (2013.01 - EP US); **C07K 5/0806** (2013.01 - EP US); **C07K 5/0808** (2013.01 - US); **C07K 5/081** (2013.01 - EP US); **C07K 5/0812** (2013.01 - US); **C07K 5/0823** (2013.01 - EP US); **C07K 5/0825** (2013.01 - EP US); **A61K 38/00** (2013.01 - EP US)

Citation (search report)

- [A] EP 1845104 A1 20071017 - KOWA CO [JP]
- [XPA] GRANT D. BARRY ET AL: "Novel Agonists and Antagonists for Human Protease Activated Receptor 2", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 20, 28 October 2010 (2010-10-28), pages 7428 - 7440, XP055031924, ISSN: 0022-2623, DOI: 10.1021/jm100984y
- See references of WO 2012012843A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2012012843 A1 20120202; AU 2011284801 A1 20130314; AU 2011284801 B2 20160128; EP 2598517 A1 20130605; EP 2598517 A4 20141126; EP 2598517 B1 20190626; JP 2013538192 A 20131010; JP 5883863 B2 20160315; US 2013184226 A1 20130718; US 2015038402 A1 20150205; US 8927503 B2 20150106; US 9701711 B2 20170711

DOCDB simple family (application)
AU 2011000959 W 20110728; AU 2011284801 A 20110728; EP 11811656 A 20110728; JP 2013520930 A 20110728; US 201113812728 A 20110728; US 201414519383 A 20141021